Quote:

---

Thanks, Ohm. It's 30 patients per arm, but your point remains the same.

---

The second DMSB safety evaluation, which involves both 350mg and 750mg arms, is when 20 patients complete one month of treatment. They would also look at efficacy at that time. They will most likely do another safety and efficacy evaluation when 30 patients from both arms have completed the course of treatment. A switch to all patients at 700mg could happen at either point but that happening at one month would be much more preferable.

Quote:

---

And Leron would work to a degree with single allele, I guess? Since there would be some CCR5 expression?

---

Leronlimab would work to a lesser degree with single allele but with single allele there might be a less dire disease state to begin with. I've tried to track down the level of CCR5 expression with single allele to no avail. It might be 50% of non-deletion CCR5. In a disease state given the feedback loops from other proteins driving CCR5 expression it might be a bit higher.